I te 22 o Hānuere, 2025, i whakaputaina e te "Nature Medicine" ngā hua o te cadonilimab, he antibody bispecific PD-1/CTLA-4 i whakawhanakehia motuhaketia e Akeso, i te taha o te oxaliplatin me te capecitabine, hei rongoā tuatahi mō te adenocarcinoma puku, gastroesophageal junction (G/GEJ) kāore e taea te tango, te horapa rānei, i roto i tētahi rangahau haumanu Wāhanga III (COMPASSION-15/AK104-302).I mua i te wā i whakapuakina ā-waha ai ngā hua o te rangahau COMPASSION-15 i te Hui-ā-Tau o te American Association for Cancer Research (AACR) 2024.
He rangahau matapōkere tēnei, he matapo-rua, he whakahaere-placebo-whakahaere. Ko ngā tūroro whai mana he pakeke me te adenocarcinoma G/GEJ kāore i rongoatia, kāore e taea te tango, kua ahu whakamua ā-rohe, kua horapa rānei. I matapōkeretia ngā tūroro 1:1 kia whiwhi cadonilimab (10 mg kg−1 ia 3 wiki) me te placebo me te chemotherapy (ia 3 wiki). Ko te mutunga tuatahi ko te oranga whānui (OS) i roto i te taupori e hiahia ana ki te rongoā (taumata hiranga kotahi-taha, P = 0.025). Ko ngā mutunga tuarua ko te OS i roto i ngā tūroro me te kaute pai PD-L1 ≥5, te oranga kore-haere, te tere urupare whāinga, te roa o te urupare me te haumaru. I te 18 o Ākuhata 2023, 610 ngā tūroro mai i te 75 pokapū rangahau i matapōkeretia ki te cadonilimab (n = 305) placebo rānei (n = 305). I te roanga o te arotakenga waenga o te 18.7 marama, he roa ake te roanga o te OS waenga o te rōpū cadonilimab (14.1 versus 11.1 marama; ōwehenga mōrearea (HR) 0.66; 95% wā whakawhirinaki (CI) 0.54–0.81; P < 0.001) i te rōpū placebo. I tutuki te pito whakamutunga tuatahi. Ko te roanga o te oranga kore-haere whakamua waenga ko 7.0 marama versus 5.3 marama (HR 0.53, 95% CI 0.44–0.65). Ko te OS waenga i ngā tūroro me te kaute pai PD-L1 ≥5 he 15.3 marama versus 10.9 marama (HR 0.58, 95% CI 0.41–0.82). Ko te reiti urupare whāinga ko 65.2% versus 48.9% me te roanga urupare waenga o te 8.8 marama versus 4.4 marama. I puta ngā pānga kino e pā ana ki te maimoatanga taumata ≥3 i roto i te 65.9% o te rōpū cadonilimab me te 53.6% o te rōpū placebo, ā, ko ngā mea tino kitea ko te hekenga o te maha o ngā pereti toto, te hekenga o te maha o ngā neutrophil me te anemia. Ko te nuinga o ngā pānga kino e pā ana ki te ārai mate he taumata 1, 2 rānei. Kāore i kitea he tohu haumaru hou. Nā te Cadonilimab me te chemotherapy i whakapai ake te OS me te kōtaha haumaru e taea te whakahaere i roto i ngā tūroro me te adenocarcinoma G/GEJ matatau.
Ko te werohanga Cadonilimab he rongoā hou, tuatahi o te akomanga PD-1/CTLA-4 rua-motuhake i whakawhanakehia i roto i te whare. I te 29 o Hune, 2022, kua whakaaetia te Cadonilimab e te NMPA o Haina mō te maimoatanga o ngā tūroro mate pukupuku waha kua hoki mai, kua horapa rānei (R/M CC) i ahu whakamua i runga, i muri rānei i te chemotherapy platinum-based. I te marama o Hepetema 2024, kua whakaaetia he tohu hou mō te cadonilimab mō te maimoatanga raina tuatahi o ngā tūroro he adenocarcinoma gastric, gastroesophageal junction (G/GEJ) kua kore e taea te tango, kua horapa rānei, me te fluoropyrimidine me te chemotherapy platinum-based. I tēnei wā, kua whakaaetia e te CDE ngā tono rongoā hou mō Cadonilimab me te chemotherapy platinum-based, me te bevacizumab, me te kore rānei, mō te maimoatanga raina tuatahi o te mate pukupuku waha pumau, kua hoki mai, kua horapa rānei. Hei tāpiritanga, kei te whakahaerehia he raupapa o ngā rangahau haumanu, tae atu ki tētahi whakamātautau wāhanga III mō te rongoā tāpiri i roto i ngā tūroro he nui te mōrearea o te hokinga mai i muri i te tango whakaora o te mate pukupuku hepatocellular, kei te whai hua.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Ngā Tohutoro
https://www.nature.com/articles/s41591-024-03450-4
Te wā tuku: 21-Pepuere-2025